Donor Selection And Cell Source Summit

As the allogeneic cell therapy space continues to mature with over 150+ clinical trials currently underway, and landmark milestones achieved with the first FDA approvals for allogeneic cell products - all eyes are turning to the backbones of these cell therapies - the cell donors. The field is awakening to the challenging reality of the increased demand for donor material to meet the required dosing needs for later stage clinical trials and licensed products.

Enter the timely arrival of the inaugural Donor Selection and Cell Source Summit, the pioneering forum for cell therapy leaders within process development, supply chain, procurement, R and D and analytics, placing a spotlight focus on cell source starting material for the first time.

With experts showcasing in-depth case studies of novel technology platforms and cell sources being utilized to increase yield, and new donor characteristic screening strategies to select for 'gold-standard' donors to achieve optimal clinical results for patients.

Get caught up to speed on this dynamic space with expertise shared from the likes of Allogene, Caribou Bio, Poseida Therapeutics, and many others as the titans of industry unite to help you advance your knowledge on donor selection, management and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond.

Find out more in the event guide - https://ter.li/t8oe61

Register to attend - https://ter.li/kss0d6

Prices:
Full Conference Access - Drug Developer: USD 4297.00,
Conference + 1 Workshop - Drug Developer: USD 3648.00,
Conference Only - Drug Developer: USD 2999.00,
Full Conference Access - Academic and Research Institute: USD 3697.00,
Conference + 1 Workshop - Academic and Research Institute: USD 3148.00,
Conference Only - Academic and Research Institute: USD 2599.00,
Full Conference Access - Service Provider: USD 5297.00,
Conference + 1 Workshop - Service Provider: USD 4548.00,
Conference Only - Service Provider: USD 3799.00

Speakers: Aaron Goldman - Instructor in Medicine | Director of Drug Resistance - Brigham and Women's Hospital, Allen Feng - Founder | CSO - HebeCell, Amanda Conerty - Exec. Director Process, Analytical Development and Manufacturing - Artiva Biotherapeutics, Colleen Delaney - Founder | CSO | EVP of Research and Development - Deverra Therapeutics, Evren Alici - Associate Professor | Co-Director - NextGenNK Competence Center Karolinska Institute, Greg Whitehead - Senior Vice President | Quality - Editas Medicine, James Liu - Research Associate II - ImmuneBridge, Jennifer Collins - Vice President | Supply Chain - Poseida Therapeutics, Jesse Cotari - CSO and Co-Founder - ImmuneBridge, Juliana Vergara - Principal Scientist | Process Development - Senti Biosciences, Kevin King - Senior Director of Donor Center Strategy and Growth - BioIVT, Kevin Liao - Associate Director | Supply Chain - Caribou Bio, Lavakumar Karyampudi - Director | Cell Therapy and Facility - Moffitt Cancer Center, Martin Maiers - Vice President | Research - Be The Match BioTherapies, Nina Horowitz - Head of Research | NK Therapeutics - ImmuneBridge, Patrick Hanley - Chief and Director | Cellular Therapy Program - National Children's Hospital, Stacey Cranert - Director | Immunoncology - Poseida Therapeutics, Will Bobbitt - Senior Research Associate I - Senti Biosciences, Ying He - Director - Allogene

Others Details

Brochure: https://go.evvnt.com/1900606-3?pid=6581